Who Is Training the Next Generation of Journal Editors and Reviewers? - Sompop Bencharit
@vslim.bsky.social
oncodaily.com/voices/sompo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.
Thanks @oncodaily.bsky.social for amplifying the authors’ work in JTO! Looking forward to 2026.
@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lcsm
Bring it on!
#ScholarlyPublishing #ResearchIntegrity
🆕Just published🆕 #LCAM25 Editorial from #JTO Editor-in-Chief Alex Adjei:
"Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal"
🔗 Read the full article here: www.jto.org/article/S155...
@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #LCSM
Getting ready for #IASLC Asia Conference on Lung Cancer this week!
Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person.
#ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication
#WCLC25 It takes a village!
Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!
@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR
#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR.
@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing
#JTO & #JTOCRR Editorial Reception
This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference.
@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social
@iaslc.bsky.social @jtoonline.bsky.social #WCLC25 #peerreview
#WCLC25 Reviewer Workshop - Here are the next generation of reviewers!
It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants.
@iaslc.bsky.social
#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer”
@iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview
#WCLC25 Our #JTO editors got many talents!
@drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06.
Case presentations and discussions with the panelists with global perspectives.
@iaslc.bsky.social
Read the special article at #JTO: jto.org/article/S155...
"Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction"
@jtoonline.bsky.social
🆕Special article by Lippman and colleagues in #JTO
📰Press release by UCSD: today.ucsd.edu/story/cancer...
@ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM
Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports.
#LCSM #LungCancer
www.jtocrr.org/article/S266...
✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib
🆓 access: www.jto.org/article/S155...
📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155...
📎 Accompanying editorial: www.jto.org/article/S155...
@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM
🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee
🆓 access to full texts 🔗 jto.org/article/S155...
@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer
🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee
🔗 www.jto.org/article/S155...
#OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social
Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!
🗳️ Vote for him to make a difference in the lung cancer sphere!
🔗 www.iaslc.org/2025-preside...
@jtoonline.bsky.social #JTO
Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election!
I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations.
@iaslc.bsky.social
@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study
www.jto.org/article/S155...
The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
www.jto.org/article/S155...
These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.
